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Abstract
Objectives: Systemic sclerosis (SSc) is a rare disease of connective tissue, manifestations of which 
may vary in different geographical areas. We aimed to describe the clinical portrait of patients with 
SSc in Dnipropetrovsk region and to investigate how initial clinical and laboratory characteristics are 
connected with the presence of hypertension in SSc onset.
Material and methods: Patients were enrolled to this study from the registry of SSc patients, es-
tablished in the Rheumatology Department, Mechnikov Dnipropetrovsk Regional Clinic, Dnipro. This 
registry contains histories of new cases of SSc from 1993 to 2014. Patients are followed-up and 
receive treatment according to EULAR and local standards. Diagnosis of SSc was based on ACR 
and EULAR Criteria for systemic Sclerosis. Two patients developed scleroderma renal crisis during 
follow-up. This report is a cross-sectional study. We analysed only data of the first visit to a rheu-
matologist.
Results: In total 148 patients (median age [IQR] – 47 [40; 52] years) fulfilled the inclusion criteria. 
Male/female ratio was 1 : 20.1. The most frequent clinical signs were Raynaud’s phenomenon and 
arthritis. The prevalence of skin lesion in dcSSc patients was twice as high as in lcSSc patients. 
Pulmonary fibrosis occurred significantly more commonly in dcSSc patients. Hypertension occurred 
in 26–33% in both groups. Patients with hypertension at the SSc onset were seven years older than 
normotensive patients. More hypertensive patients were classified as lcSSc. Mean GFR was dramat-
ically lower in hypertensive patients.
Conclusions: The most common clinical form in our study was diffuse cutaneous subset of SSc. 
Hypertension in patients with SSc may be associated with local cutaneous subset of SSc and renal 
impairment. The strongest predictors of clinical form of SSc are signs of fibrosis (skin lesion and 
pulmonary fibrosis) and inflammation (arthritis and elevated CRP).
Key words: systemic sclerosis, registry, arterial hypertension.
Introduction
Systemic sclerosis (SSc) is a rare disease of connec-
tive tissue that may affect different organs and is char-
acterised by immune, vascular, and fibrotic disruptions. 
Because of the low prevalence of SSc in the population, 
providing clinical trials and wide observations may be 
challenging. To overcome the lack of reliable epidemio-
logical data, different medical and scientific communi-
ties have established registries to collect and analyse 
data about SSc. Investigating the patient population is 
important because the incidence, prevalence, and clini-
cal features of SSc throughout the world differ. 
Epidemiological data from South Australia show an 
incidence rate of SSc 22.8 (95% CI) of new cases per 
million [1] (data from 1993–1999), while in Greece the 
incidence rate is 11 new cases per million (data from 
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1981–2002) [2]. Differences in the assessment of inci-
dence can be explained by different ethnic and genetic 
compositions of different regions, climatic conditions, 
exposures, etc. [3, 4].
Analysis of registries’ data allows us to determine 
the factors that can impact prognosis of the disease. For 
example, data from the EULAR registry have shown that 
deterioration of skin fibrosis can be predicted by initial 
modified Rodnan skin score [5]. In the DUO registry sev-
eral factors were revealed, capable of predicting devel-
opment of incident gangrene [6].
The high heterogeneity of clinical manifestations has 
prompted internists to classify SSc to facilitate its man-
agement. In 1980 the American College of Rheumatolo-
gy presented the Systemic Sclerosis Classification Crite-
ria, which were précised in 1988, 2001, and 2013 [7–10]. 
Now we have highly specific and sensitive criteria that 
allow us to distinguish different forms of SSc. But still 
there are some patients who cannot be classified. Us-
ing registries helps rheumatologists to find symptoms 
that are useful in distinguishing subsets. Minier et al., 
in research based on the EUSTAR registry, declared puffy 
fingers to be a pivotal sign for suspicion of systemic 
sclerosis [11]. In our investigation we aimed to describe 
the clinical portrait of patients with SSc in the Dniprope-
trovsk region (central Ukraine). This region is character-
ised by multinational composition. Officially, 80% of the 
population of the region are Ukrainians, but considering 
the complicated history of Ukraine (frequent changes of 
state power and migration) we assume a high diversity 
of nationalities represented here.
In our previous studies we learned that hypertension 
in SSc patients has heterogeneous aetiology and can be 
predicted by age > 45 years, presence of skin lesions, and 
elevated markers of inflammation [12]. But still there is 
a lack of information about the role of hypertension in 
progression of SSc. We know about the prevalence of 
hypertension on the onset of SSc [13, 14]. Patients with 
rheumatoid arthritis and inflammatory joint diseases 
have higher cardiovascular risk, compared to the gen-
eral population. There are recommendations for car-
diovascular risk management in this group of patients 
issued by EULAR [15]. These recommendations could be 
used for SSc patients also, but we assume that because 
of the specific genesis of scleroderma, such patients re-
quire a separate approach.
It is known that hypertension can cause vascular 
changes similar to those that occur in SSc [16], and prob-
ably these two conditions may interact with each other. 
Also, interaction between hypertension and SSc-related 
vascular damage may result in a separate phenotype of 
hypertension in such patients. This thesis is fair at least 
for SSc-related pulmonary hypertension (PAH) – recent 
studies have shown that idiopathic PAH is significantly 
histologically different from SSc-related pulmonary hy-
pertension [17]. There are suggestions that SSc-related 
renal changes can be histologically differentiated from 
those in hypertension [18]. Although there are data indi-
cating that vascular changes in SSc patients are primary 
to hypertension rather than secondary, they lack evi-
dence [19, 20]. In this study we aimed to investigate how 
initial clinical and laboratory characteristics are connect-
ed with the presence of hypertension in SSc onset.
Material and methods
Patients were enrolled to this study from the reg-
istry of SSc patients established in the Rheumatology 
Department, Mechnikov Dnipropetrovsk Regional Clin-
ic, Dnipro. This registry contains histories of new cases 
of SSc since 1993. Patients are followed-up and receive 
treatment according to EULAR [21] and local standards. 
Diagnosis of SSc was based on ACR (including LeRoy and 
Medsger modifications) and EULAR Criteria for Systemic 
Sclerosis [7–10]. This report is cross-sectional study. We 
analysed only data of the first visit to a rheumatologist 
from 1993 to 2014. Two patients developed scleroderma 
renal crisis (SRC) during follow-up and were excluded 
from analysis (Fig. 1). All patients gave written, informed 
consent; the study was approved by the Ethics Commit-
tee at the Mechnikov Dnipropetrovsk Regional Clinic. 
Patients were classified according to LeRoy and 
Medsger’s modifications of ACR Criteria [8, 9] into the 
following groups: limited SSc (pre-SSc) [22], limited cu-
taneous SSc (lcSSc), diffuse cutaneous SSc (dcSSc), and 
“other” (patients with localised forms of SSc and over-
lap-syndrome were included into this group). Limited 
SSc was defined as the presence of Raynaud’s phenom-
enon (objective) plus any one of the following: SSc-type 
Fig. 1. Study design.
Register of patients 
with SSc 
(n = 190)
n = 187
Patients with localized SSc, 
overlap-syndrome and preSSc 
(n = 41)
Uncertain diagnosis of SSc 
(n = 1), patients with SRC 
(n = 2)
Patients in analysis 
(n = 146)
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nailfold capillary pattern or SSc selective autoantibod-
ies; or Raynaud’s phenomenon (subjective only) plus 
both SSc-type nailfold capillary pattern and SSc selec-
tive autoantibodies. Limited cutaneous subset was de-
fined in patients with criteria for pre-SSc plus distal cu-
taneous changes. Diffuse cutaneous subset was defined 
in patients with criteria for pre-SSc plus proximal cuta-
neous changes. Patients with pre-SSc, localised forms, 
and overlap-syndrome were excluded from the analysis 
because of heterogeneity of this group and the absence 
of a clear definition of pre-SSc.
Raynaud’s phenomenon was defined using clinical 
(development of the paleness of skin of the fingers in 
response to cold exposure or emotional stress) and 
nailfold video capillaroscopy. Skin lesion was defined 
if a patient had focal swelling, induration, or atrophy, 
regardless of localisation. Arthritis was regarded as 
swelling and tenderness in one or more joints. Presence 
of lung fibrosis was assessed using chest X-ray or CT 
examination. Gastrointestinal involvement was diag-
nosed in the case of complaints of dysphagia accompa-
nied by changes on gastroscopy or barium swallow test. 
Hypertension was diagnosed using local standards and 
2013 ESH/ESC Guidelines for the management of arteri-
al hypertension [23].
Anaemia was diagnosed as a haemoglobin level 
> 130 g/l in males and > 120 g/l in females. The level of 
leukocytes was regarded abnormal if it was higher than 
9 × 109/l or lower than 4 × 109/l. The level of thrombocytes 
was regarded as abnormal if it was higher than 320 × 
109/l or lower than 180 × 109/l. We used a cut-off point of 
25 mm/hour for erythrocyte sedimentation rate (ESR) be-
cause of the proven impact of that value on the prognosis 
[24]. Glomerular filtration rate (GFR) was estimated using 
the CKD-EPI formula [25]. For detection of the proteinuria 
we used urine microelectrophoresis (> 0.3 and < 3.5 g/ 
24 hours according to local standards). We used standard 
methods of measurement for C-reactive protein (CRP) 
and rheumatoid factor (RF). Mean pressure in pulmonary 
artery (PAPm) was assessed during Doppler echocardio-
gram. In multivariate logistic regression we used protein-
uria as a marker of vascular damage [26].
The data was the most complete for age, gender, 
clinical manifestations (Raynaud’s phenomenon, arthri-
tis, skin lesion, pulmonary fibrosis, hypertension), anae-
mia, leukocyte count, ESR, cylindruria, and proteinuria 
with missing data for the mentioned values < 10%. The 
percentage of missing data for the rest of the variables 
ranged between 20 and 50%, being the highest for GFR 
(70.3%). The percentage presented in the tables along 
with absolute values reflects valid proportion.
Data were analysed using Microsoft Office and SPSS 
17.0. The type of data distribution was assessed with 
Kolmogorov-Smirnov test, and differences in variances 
of compared groups were assessed with Levene’s test. 
Normally distributed data were described with mean 
and standard deviation (SD), and non-normally distrib-
uted data were described with median and interquartile 
range (IQR). Data with normal distribution and equal 
variance were compared using independent T-test. In 
the case of violation of assumptions of data distribution, 
normality or homogeneity of variance U-Mann-Whitney 
was performed. We used two-tailed Fisher’s exact test 
to compare categorical data. Investigation of predictors 
of clinical forms was performed using multivariate logis-
tic regression with stepwise forward method of entering 
variables. Predictors in the model were: symptoms of 
excessive fibrosis (skin lesion, pulmonary fibrosis), signs 
of vasculopathy (hypertension, proteinuria), and signs 
of inflammation (arthritis, elevated levels of CRP, RF or 
ESR). We considered p-values < 0.05 to be significant. 
Results
We analysed data of 148 patients (seven males and 
139 females, median age [IQR] 47 [40; 52] years). Male/
female ratio was 1 : 19.8. Males in our study contributed 
only to the dcSSc group (Table I).
The median age of the disease onset in our study 
was slightly higher in lcSSc compared to dcSSc patients. 
The most frequent clinical signs were Raynaud’s phe-
nomenon and arthritis. Prevalence of RP and arthritis 
was high in both groups. Prevalence of skin lesion in 
dcSSc patients was twice as high as in lcSSc patients 
(p < 0.001). Pulmonary fibrosis occurred significantly 
more often in dcSSc than in lcSSc patients (p = 0.01). The 
prevalence of gastrointestinal complications was slight-
ly higher in patients with lcSSc. Hypertension occurred 
in 26–33% in both groups. Among laboratory signs we 
observed higher prevalence of anaemia, elevated CRP 
(p = 0.03), proteinuria, and cylindruria in the dcSSc 
group. Mean GFR was higher lcSSc. PAPm was normal in 
both groups (Table I).
Patients who had hypertension at SSc onset were 
seven years older than normotensive patients. More 
hypertensive patients were classified as lcSSc, but not 
significantly. Hypertension at SSc onset was associated 
with higher prevalence of skin lesion, arthritis, pulmonary 
fibrosis, abnormal levels of thrombocytes and ESR, and 
cylindruria. The prevalence of gastrointestinal complica-
tions in hypertensive patients was higher. The absence 
of hypertension was associated with higher prevalence 
of anaemia. In hypertensive patients PAPm was slightly 
higher and mean GFR was dramatically lower (Table II).
We aimed do distinct clinical and laboratory signs of 
SSc at the disease onset that could help rheumatologist 
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Table I. General clinical and laboratory characteristics
Patient characteristics Total lcSSc dcSSc p-value
n (valid %)
Number of patients 146
(100)
39
(26.8)
107
(73.2)
Median age, years [IQR] 47 [40; 52] 48 [41; 51] 46 [40;52] 0.74
Female 139  (95.2) 39 (100.0) 100 (93.5) 0.12
Male 7 (4.8) 0 (0.0) 7 (6.5) 0.12
Raynaud’s phenomenon 127 (92.7) 35 (94.6) 92 (92.0) 0.72
Skin lesion 90 (61.6) 14 (35.9) 76 (71.0) < 0.001
Arthritis 120 (82.2) 34 (87.2) 86 (80.4) 0.46
Pulmonary fibrosis 37 (25.3) 4 (10.3) 33 (30.8) 0.01
Gastrointestinal involvement 77 (65.8) 18 (75.0) 59 (63.4) 0.28
Oesophagus* 52 (54.7) 15 (58.8) 37 (52.8) 0.53
Hypertension 39 (26.7) 12 (30.8) 27 (25.2) 0.53
Anaemia 51 (35.4) 10 (25.6) 41 (39.0) 0.17
Abnormal leukocytes 27 (19.1) 5 (12.8) 22 (21.6) 0.33
Abnormal thrombocytes 25 (24.3) 6 (22.2) 19 (25.0) 1.0
ESR > 25 mm/h 28 (20.4) 6 (16.2) 22 (22.0) 0.63
CRP > 10 mg/l 22 (19.1) 2 (6.3) 20 (24.1) 0.03
RF > 14 IU/ml 10 (10.1) 1 (3.3) 9 (13.0) 0.27
Proteinuria 43 (31.4) 10 (27.0) 33 (33.0) 0.54
Cylindruria 14 (10.6) 3 (8.6) 11 (11.3) 0.76
Mean GFR, ml/min (SD) 88.5 (22.9) 93.7 (23.1) 88.0 (23.1) 0.63
Median PAPm, mm Hg [IQR] 23 [17; 32] 23 [16; 32] 23 [17; 32] 0.77
lcSSc – limited cutaneous subset of SSc; dcSSc – diffuse cutaneous subset of SSc; ESR – erythrocyte sedimentation rate; CRP – C-reactive 
protein; RF – rheumatoid factor; GFR – glomerular filtration rate; PAPm – mean pulmonary arterial pressure; IQR – interquartile range;  
SD – standard deviation
* Oesophageal involvement was isolated from the manifestation of the digestive system as an important risk factor for poor prognosis.
to predict the form of SSc. We used parameters from 
the registry that had the lowest levels of missing data 
and distributed them into the following groups: markers 
of inflammation (arthritis, elevated CRP, ESR, and RF); 
markers of fibrosis (pulmonary fibrosis, skin lesion); and 
markers of vascular damage (hypertension, proteinuria). 
Arthritis was strongly associated with lcSSc. Elevated 
CRP, skin lesion, and pulmonary fibrosis were associated 
with dcSSc disease onset. Pulmonary fibrosis and ele-
vated CRP were unlikely in lcSSc patients (Table III).
Discussion
The median age [IQR] of the disease onset in our 
study was 47 (40; 52) years, and it was similar to data 
reported in EULAR and Spanish registries. But we used 
the first visit to a rheumatologist as the onset of the 
disease, whereas our European colleagues used for the 
same purpose the time of RP appearance. Consequently, 
the real age of the SSc onset may be lower and it may 
be approximated to the mean age in the pre-SSc group. 
The male/female ratio of our patients was higher than 
in other European countries and was comparable only to 
a Japanese cohort [27].
As lcSSc were classified 27.1% of patients and 72.9% 
– as dcSSc. These findings are in contrast to those in 
available to other reports [13, 14, 22]. Among all reported 
data, a German cohort had the most similar percentage 
of lcSSc and dcSSc patients (45.5% and 32.7%, respec-
tively) [13]. This may be explained by late addressing of 
these patients to a rheumatologist, and it may be as-
sumed that the most severe cases were referred to our 
centre. Differences in patient distribution could be also 
influenced by different ethnic composition of patients 
and the climatic conditions where they live. Almost 14% 
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of the patients of our registry were classified as pre-SSc; 
interestingly, it was higher, than reported in the Spanish 
registry (4%) [22]. We used LeRoy and Medsger criteria 
for classification of these patients, but due to the ab-
sence of a clear definition of this form we excluded them 
from the analysis [9, 28]. 
In our study we observed lower frequency of pulmo-
nary fibrosis and higher frequency of arthritis and pro-
teinuria, compared to data from European registries. The 
prevalence of hypertension in our study was higher than 
in the EULAR report [14]. A similar association of lcSSc and 
hypertension was evident in the German registry [13]. 
Mean systolic pressure in the pulmonary artery in our 
study was lower than in the Spanish registry [22]. As we 
expected, clinical and laboratory signs of organ damage 
were revealed more often in patients of the dcSSc group.
Table II. Initial clinical and laboratory characteristics depending on the presence of hypertension
Parameter Hypertension,
n (valid %)
No hypertension,
n (valid %)
p-value
N 39 (100) 107 (100)
Female 36 (92.3) 103 (96.3) 0.38
Male 3 (7.7) 10 (3.7) 0.38
Median age, years [IQR] 51 [47;57] 44 [36;50] < 0.001
lcSSc onset 12 (30.8) 27 (25.2) 0.53
dcSSc onset 27 (69.2) 80 (74.8) 0.53
Raynaud’s phenomenon 37 (100) 90 (90.0) 0.06
Skin lesion 28 (71.8) 62 (57.9) 0.17
Arthritis 34 (87.2) 86 (80.4) 0.46
Pulmonary fibrosis 13 (31.3) 24 (22.4) 0.20
Gastrointestinal involvement 21 (72.4) 56 (63.6) 0.38
Oesophagus 19 (67.8) 33 (49.2) 0.09
Anaemia 10 (25.6) 41 (39.0) 0.17
Abnormal leukocytes 6 (15.8) 21 (20.4) 0.63
Abnormal thrombocytes 6 (25.0) 19 (24.1) 1.0
ESR > 25 mm/h 9 (26.5) 19 (18.4) 0.33
CRP > 10 mg/l 4 (16.7) 18 (19.8) 1.0
RF > 14 IU/ml 3 (12.0) 7 (9.7) 0.71
Proteinuria 11 (28.2) 32 (32.0) 0.83
Cylindruria 7 (17.9) 7 (7.3) 0.05
Mean GFR, ml/min (SD) 77.8 (28.8) 91.2 (20.7) 0.11
Median PAPm, mm Hg [IQR] 26 [23; 35] 22 [16; 32] 0.21
lcSSc – limited cutaneous subset of SSc; dcSSc – diffuse cutaneous subset of SSc; ESR – erythrocyte sedimentation rate; CRP – C-reactive 
protein; RF – rheumatoid factor; GFR – glomerular filtration rate; PAPm – mean pulmonary arterial pressure; IQR – interquartile range; 
SD – standard deviation
Table III. Multivariate analysis of predictors of clinical forms of systemic sclerosis
Outcome Predictor Risk ratio p value
lcSSc onset Pulmonary fibrosis 0.076 0.017
Arthritis 8.294 0.002
CRP > 10 mg/l 0.204 0.058
dcSSc onset Skin lesion 4.923 0.001
Pulmonary fibrosis 6.436 0.024
CRP > 10 mg/l 4.568 0.039
lcSSc – limited cutaneous subset of SSc; dcSSc – diffuse cutaneous subset of SSc; CRP – C-reactive protein
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We revealed a strong association between age and 
the presence of hypertension in SSc patients. We found 
that hypertension occurs more frequently in lcSSc than 
in dcSSc patients; hypertension is also less common in 
pre-SSc patients. These findings fit well with data from 
the EULAR report, in which they claimed hypertension to 
be connected with “not dcSSc” and “late RP onset” [14]. In 
general, hypertensive patients showed higher prevalence 
of signs of organ damage. We found the most significant 
discrepancy in frequencies of signs of renal impairment. 
This fact could be explained by longer disease duration 
(because of late diagnosis of SSc) or late onset of the dis-
ease (which may be associated with poor prognosis).
Multivariate logistic regression has shown that the 
strongest predictive power was from signs of fibrosis and 
inflammation. However, the association between hyper-
tension and clinical form of SSc, revealed in the previous 
section, was not confirmed. Results of this analysis fit 
well with reported analyses of disease manifestations [14, 
22]. The only discrepancy we found was the association of 
arthritis with lcSSc in our study, whereas in the Spanish 
registry it was associated with dcSSc.
As far as we know, this is the first analysis of associa-
tion between hypertension and severity of SSc. The data 
we gathered allow us to suggest that hypertension could 
be one of the pivotal signs of SSc, capable of influencing 
the course of the disease. The fact that hypertension is 
a sign that could relatively easily be revealed and con-
trolled adds importance to our findings.
Conclusions
The most common clinical form of SSc in our study 
was diffuse cutaneous subset of SSc. Hypertension in 
patients with SSc may be associated with local cutane-
ous subset of SSc and renal impairment. The strongest 
predictors of clinical form of SSc are signs of fibrosis 
(skin lesion and pulmonary fibrosis) and inflammation 
(arthritis and elevated CRP).
Limitations
Data in this study were collected from patients living 
in Eastern Europe (Dnipro region, Central Ukraine).
We assumed the disease onset to be the time of the 
first visit to a rheumatologist, whereas other investiga-
tors used the time of Raynaud’s phenomenon onset for 
the same purpose.
The authors declare no conflict of interest.
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